We've updated our Privacy Policy to make it clearer how we use your personal data.
We use cookies to provide you with a better experience, read our Cookie Policy
EP22825
Abstract: Alzheimer's disease (AD) is the most common cause of dementia characterized by impaired memory and cognitive dysfunction due to neurodegeneration. The predicted increase in AD morbidity coupled with the socioeconomic impact of the disease has necessitated the urgent development of an effective therapy. However, the currently available models of AD are challenging and a more humanized, scalable assay system is required to better understand the disease and identify novel therapies.
There are two methods to develop AD model cells based on human induced pluripotent (iPS) cells. The first method uses targeted genetic modification of human iPS cells, and the other involves the production of human iPS cells from patients with AD. We supply both types of AD model cells depending on request.
In this poster, we describe how we developed the AD model cells (ReproNeuro Ach-ADTM and ReproNeuro Glu-ADTM ) by generating human iPS cells containing a mutant Presenilin 1 (PS1) gene, which is responsible for familial AD, and differentiating these cells into cholinergic neurons or glutamatergic neurons. In the brains of patients with AD, cholinergic neurons are damaged and the glutamate system is disrupted. To confirm whether these neurons can be used for drug screening, we performed characterization of these neurons as well as the Aβ assay. The effect of these neurons on the production of Aβ40 and Aβ42 was measured using the AlphaLISA® Human Amyloid β1-40/1-42 immunoassay kit (Perkin-Elmer) for high-throughputscreening (HTS).Summary: Alzheimer's disease model neurons were created from iPS cells to enable functional, cell-based assays for AD.
There are two methods to develop AD model cells based on human induced pluripotent (iPS) cells. The first method uses targeted genetic modification of human iPS cells, and the other involves the production of human iPS cells from patients with AD. We supply both types of AD model cells depending on request.
In this poster, we describe how we developed the AD model cells (ReproNeuro Ach-ADTM and ReproNeuro Glu-ADTM ) by generating human iPS cells containing a mutant Presenilin 1 (PS1) gene, which is responsible for familial AD, and differentiating these cells into cholinergic neurons or glutamatergic neurons. In the brains of patients with AD, cholinergic neurons are damaged and the glutamate system is disrupted. To confirm whether these neurons can be used for drug screening, we performed characterization of these neurons as well as the Aβ assay. The effect of these neurons on the production of Aβ40 and Aβ42 was measured using the AlphaLISA® Human Amyloid β1-40/1-42 immunoassay kit (Perkin-Elmer) for high-throughputscreening (HTS).Summary: Alzheimer's disease model neurons were created from iPS cells to enable functional, cell-based assays for AD.
Ask the author a question about this poster.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Related Posters
Antibody Modification and Conjugation Technologies
BOC Sciences
Lung-Disease-Related Mitochondria Studies
Joe Cohen
Liver-Disease-Related Mitochondria Studies
Joe Cohen
Improved Cellular Maintenance of Human Pluripotent Stem Cells in a Serum-Free, Xeno-Free Culture System for Clinical Applications
Deborah L.D. Maybruch, PhD¹, Philip D. Manos², Brad Hamilton³, Michelle M. Janaszak¹, Tanya Potcova¹
Kidney-Disease-Related Mitochondria Studies
Joe Cohen
